Moderna mRNA Vaccine Trial: To Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults to Prevent COVID19

Site Image

Study Overview

The Moderna mRNA-1273 vaccine is being developed to prevent COVID-19, the disease resulting from Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) infection. The study is designed to primarily evaluate the efficacy, safety, and immunogenicity of mRNA-1273 to prevent COVID-19 for up to 2 years after the second dose of mRNA-1273.

Study Description

  • The Cove Study is a Phase 3 study of an experimental vaccine against SARS-CoV-2 called mRNA-1273. 
  • This study is also known as “mRNA-1273-P301.”
  • The study vaccine was developed by ModernaTX, Inc. They are located in Cambridge, Massachusetts. Moderna specializes in developing the use of mRNA technology for vaccines and treatments for a number of diseases.
  • The study vaccine is known as an mRNA vaccine.
  • The study will enroll about 30,000 people in the US.
  • Our site is hoping to recruit widely from racially and ethnically diverse groups that have been impacted in greater numbers during the pandemic.
Please fill out the prescreener questions below to see if you pre-qualify for the study. Meeting initial criteria does not guarantee entry into the trial.
Final eligibility decision is made by the physician and clinical team, after reviewing medical records.

  • Study Identifier: 843626

Recruitment Status

Open

Check to see if you pre-qualify for the study.

Are you at least 18 years old?

BACK
Volunteer Sign up

Volunteer Sign-up

Participate in medical studies to develop new diagnostic and clinical treatments and improve current standards of care.

Sign Up Now!

If you need assistance finding a non-cancer study or if you have any questions, please email psom-ocr@pobox.upenn.edu